Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation

1. Male or female aged 18 years and over 2. Planned surgical resection of NSCLC, stage IB ≥ 4 cm, II or IIIA according to the 8th edition of TNM classification16. 1. Cohort #1: Neoadjuvant Therapy - For patients who will receive neoadjuvant therapy, enrollment occurs prior to the initiation of treatment. Patients undergoing neoadjuvant therapy who achieved tumor reduction, are eligible based on baseline radiographic staging. 2. Cohort #2: Pre-Surgery - For patients identified prior to planned surgical resection, enrollment occurs within 30 days of the planned surgery. Eligibility is based on surgical pathology. 3. Cohort #3: Post-Surgery - For patients identified post-surgical resection, enrollment occurs prior to the initiation of adjuvant therapy. Eligibility is based on surgical pathology. 3. Patients with positive margins and those requiring adjuvant radiation therapy are eligible. 4. Patients with a secondary malignancy that was treated with curative intent and without evidence of relapse for at least 5 years. 5. Willingness to undergo all study collection procedures and follow up. 6. Provision of written informed consent

1. Male or female aged less than 18 years 2. NSCLC disease other than stated above 3. Patients with a secondary malignancy that was not treated with curative intent or has had a disease relapse in the past 5 years. 4. Unwilling to undergo all study collection procedures and follow up. 5. Unable or unwilling to provide consent.